Advanced Healthcare Materials · 2024 · 15 citations · 12 references
PharmacyBioengineeringBiomedical EngineeringDrug DeliveryNanomaterialsNanoparticle Drug DeliveryDrug EncapsulationHydrogelsNanomedicineNanoparticle Delivery SystemsNanoparticle FormulationsOsteoarthritisCerium Oxide NanoparticlesChondrogenic DifferentiationCollagen Drug Delivery SystemsControlled ReleaseHydrogel Delivery SystemsIron Oxide NanoparticlesReactive Oxygen Species-responsive NanoparticlesSustained Release Biomaterials
Abstract Osteoarthritis (OA), characterized by chronic inflammation and cartilage degeneration, significantly affects over 500 million people globally. Nanoparticles have emerged as promising treatments for OA; however, current strategies often employ a single type of nanoparticle targeting specific disease stages, limiting sustained therapeutic efficacy. In this study, a novel collagen hydrogel is introduced, thiol crosslinked collagen‐cerium oxide‐poly(D,L‐lactic‐co‐glycolic acid) microspheres encapsulating nanoparticles (CSH‐CeO 2 ‐pFe 2 O 3 ), designed for the controlled release of cerium oxide (CeO 2 ) and ferric oxide (Fe 2 O 3 ) nanoparticles for comprehensive OA management. The sulfhydryl cross‐linked collagen matrix embeds CeO 2 nanoparticles and poly(D,L‐lactic‐co‐glycolic acid) (PLGA) microspheres encapsulating Fe 2 O 3 nanoparticles. The CSH‐CeO 2 ‐pFe 2 O 3 hydrogel exhibits enhanced mechanical strength and remarkable injectability, along with a significant promotion of cell adhesion, proliferation, and chondrogenic differentiation. Notably, the hydrogel demonstrates intelligent responsiveness to high levels of reactive oxygen species, initiating the rapid release of CeO 2 nanoparticles to address the intense inflammatory responses of early‐stage OA, followed by the sustained release of Fe 2 O 3 nanoparticles to facilitate cartilage regeneration during the proliferative phase. In a rat model with cartilage defects, the hydrogel significantly alleviates inflammation and enhances cartilage regeneration, holding substantial potential for effectively managing the pathologically complex OA.
12